Semiflow Medical UG

Business Strategies

Semiflow Medical is developing an endovascular stent that replaces deficient vein valves in the legs to treat Chronic Venous Insufficiency.

Core Technologies and Services

Prevalence of Chronic Venous Insufficiency is in average 8% of western population. The cause of the disease is the failure of damaged venous valves in the legs. The return of venous blood from the lower limbs to the heart is reduced, resulting in increased venous pressure, dilated superficial veins that become progressively more tortuous and enlarged and subsequent lower limb swelling, skin hyperpigmentation, eczema, atrophy and ulcers.

Semiflow develops an endovascular stent in cooperation with Institute for Biofluidmechanics of Regensburg Center of Biomedical Engineering (RCBE) Prof. Dr. Krenkel at the OTH Regensburg. The Semiflow endovascular stent replaces the deficient vein valves, directing blood-flow in the preferred direction to the heart and preventing blood reflux to the legs, consequently reducing leg swelling, varicosis, skin diseases and ulcerations.

Patent, Licenses, Co-operations

Semiflow Medical is the exclusive owner of the international patent.

Cooperation with Institute for Biofluidmechanics of Regensburg Center of Biomedical Engineering (RCBE) Prof. Dr. Krenkel at the OTH Regensburg.